Tóm tắt
Xơ cứng bì toàn thể là một bệnh lí tự miễn phức tạp do viêm, tổn thương mạch máu và xơ hoá da và các cơ
quan nội tạng như tiêu hoá, hô hấp, thận, tim mạch, cơ xương khớp. Nguyên nhân gây bệnh là chưa rõ mặc dù
một số yếu tố gene, môi trường được ghi nhận đóng vai trò trong cơ chế sinh bệnh. Xơ cứng bì toàn thể là bệnh
lí có tỉ lệ tử vong cao trong nhóm các bệnh lí thấp khớp, mặc dù đã có cải thiện trong liệu pháp điều trị trong vài
thập niên qua nhưng tỉ lệ sống còn cải thiện một cách khiêm tốn. Gần đây những nghiên cứu cho thấy những
hiểu biết mới về cơ chế bệnh sinh ở các mức độ gene, tế bào, các phương pháp tiếp cận mới trong đánh giá tổn
thương cơ quan, tự kháng thể cũng như đánh giá hiệu quả của các liệu pháp điều trị, các chỉ điểm cho tiên lượng
bệnh. Trong bài tổng quan này sẽ điểm lại những kiến thức mới về bệnh xơ cứng bì qua những công bố gần đây.
| Đã xuất bản | 24-04-2025 | |
| Toàn văn |
|
|
| Ngôn ngữ |
|
|
| Số tạp chí | Tập 15 Số 1 (2025) | |
| Phân mục | Tổng quan | |
| DOI | 10.34071/jmp.2025.1.2 | |
| Từ khóa | xơ cứng bì toàn thể, bệnh sinh, biểu hiện lâm sàng, điều trị systemic sclerosis, pathogenesis, clinical manifestations, treatment |
công trình này được cấp phép theo Creative Commons Attribution-phi thương mại-NoDerivatives 4.0 License International .
Bản quyền (c) 2025 Tạp chí Y Dược Huế
Volkmann, E.R., K. Andréasson, and V. Smith, Systemic sclerosis. The Lancet, 2023. 401(10373): p. 304-318.
Parker, M.J.S., et al., Multiple serum biomarkers associate with mortality and interstitial lung disease progression in systemic sclerosis. Rheumatology, 2024: p. keae110.
Machhua, S., et al., Human leukocyte antigen association in systemic sclerosis patients: our experience at a tertiary care center in North India. Frontiers in Immunology, 2023. 14: p. 1179514.
Lomeli-Nieto, J.A., et al., TGFB1 mRNA expression and frequency of the+ 869T> C and+ 915G> C genetic variants: impact on risk for systemic sclerosis. Clinical and Experimental Medicine, 2023. 23(4): p. 1349-1357.
Tan, T.C., et al., Gut microbiome profiling in systemic sclerosis: a metagenomic approach. Clin Exp Rheumatol, 2023. 41(8): p. 1578-1588.
Martínez-López, J., et al., FLT3 functional low-frequency variant rs76428106-C is associated with susceptibility to systemic sclerosis. Rheumatology, 2023. 62(SI): p. SI138-SI142.
Khedr, A.M., et al., miRNA-133 and lncRNA-H19 expressions and their relation to serum levels of PKM2 and TGF-β in patients with systemic sclerosis. Non-coding RNA Research, 2024. 9(1): p. 253-261.
Berkowitz, J.S., et al., Cell Type–Specific Biomarkers of Systemic Sclerosis Disease Severity Capture Cell‐Intrinsic and Cell‐Extrinsic Circuits. Arthritis & Rheumatology, 2023. 75(10): p. 1819-1830.
McMahan, Z.H., et al., Anti‐Gephyrin Antibodies: A Novel Specificity in Patients With Systemic Sclerosis and Lower Bowel Dysfunction. Arthritis & Rheumatology, 2024. 76(1): p. 92-99.
Denton, C.P., et al., Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis. Annals of the Rheumatic Diseases, 2023. 82(9): p. 1205-1217.
Sanges, S., et al., Biomarkers of haemodynamic severity of systemic sclerosis-associated pulmonary arterial hypertension by serum proteome analysis. Annals of the rheumatic diseases, 2023. 82(3): p. 365-373.
Jee, A.S., et al., A composite serum biomarker index for the diagnosis of systemic sclerosis–associated interstitial lung disease: a multicenter, observational cohort study. Arthritis & Rheumatology, 2023. 75(8): p. 1424-1433.
Motta, F., et al., Proteomic aptamer analysis reveals serum biomarkers associated with disease mechanisms and phenotypes of systemic sclerosis. Frontiers in Immunology, 2023. 14: p. 1246777.
Kayaalp, M., et al., Semaphorin 3A levels in vascular and nonvascular phenotypes in systemic sclerosis. Laboratory medicine, 2023. 54(6): p. 646-651.
Mismetti, V., et al., Proteomic biomarkers for survival in systemic sclerosis-associated pulmonary hypertension. Respiratory Research, 2023. 24(1): p. 273.
Zhang, X., et al., Diagnostic accuracy and predictive value of autoantibody profiles in patients with systemic sclerosis: a single-center study. Clinical Rheumatology, 2023. 42(5): p. 1297-1306.
Wallwork, R.S., A.A. Shah, and L. Casciola-Rosen, Association between anti-SSSCA1 antibodies and cancer in systemic sclerosis. Rheumatology, 2023. 62(7): p. 2539- 2543.
Öztürk, Ö., et al., Performance of myotonometer in the assessment of skin involvement in systemic sclerosis. Clinical Rheumatology, 2024. 43(2): p. 695-705.
Richardson, C., et al., Cumulative disease damage and anti-PM/Scl antibodies are associated with a heavy burden of calcinosis in systemic sclerosis. Rheumatology, 2023. 62(11): p. 3636-3643.
Poonia, K., et al., Brachial artery flow-mediated dilation in patients with systemic sclerosis: an experience from tertiary care center from North India. Clinical Rheumatology, 2023. 42(7): p. 1827-1832.
Pellicano, C., et al., Role of kinurenic acid in the systemic sclerosis renal involvement. Clinical and Experimental Medicine, 2023. 23(5): p. 1713-1719.
Fairley, J.L., et al., Clinical characteristics and survival of pulmonary arterial hypertension with or without interstitial lung disease in systemic sclerosis. Arthritis Research & Therapy, 2023. 25(1): p. 77.
Dupont, A., et al., Dual-energy CT lung perfusion in systemic sclerosis: preliminary experience in 101 patients. European Radiology, 2023. 33(1): p. 401-413.
Rivet, V., et al., High prevalence of malnutrition in systemic sclerosis: Results from a French monocentric cross-sectional study. Nutrition, 2023. 116: p. 112171.
Ivanova, K., et al., Prevalence of polyneuropathies among systemic sclerosis patients and impact on health-related quality of life. Neurologia i Neurochirurgia Polska, 2023. 57(2): p. 206-211.
Keyes‐Elstein, L., et al., Clinical and molecular findings after autologous stem cell transplantation or cyclophosphamide for scleroderma: handling missing longitudinal data. Arthritis care & research, 2023. 75(2): p. 307-316.
Kuzumi, A., et al., Long-term outcomes after rituximab treatment for patients with systemic sclerosis: follow-up of the DESIRES trial with a focus on serum immunoglobulin levels. JAMA dermatology, 2023. 159(4): p. 374-383.
Denton, C.P., et al., Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trial. Rheumatology, 2023. 62(5): p. 1870-1876.
Campochiaro, C., et al., Real-life efficacy and safety of nintedanib in systemic sclerosis-interstitial lung disease: Data from an Italian multicentre study. RMD open, 2023. 9(1): p. e002850.
Griffiths-Jones, D.J., et al., A Phase II randomized controlled trial of oral prednisolone in early diffuse cutaneous systemic sclerosis (PRedSS). Rheumatology, 2023. 62(9): p. 3133-3138.
Spiera, R., et al., Efficacy and safety of lenabasum, a cannabinoid type 2 receptor agonist, in a phase 3 randomized trial in diffuse cutaneous systemic sclerosis. Arthritis & Rheumatology, 2023. 75(9): p. 1608-1618.
Fukasawa, T., et al., Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: Analysis of a single-arm, open-label, phase 1 trial. Journal of the American Academy of Dermatology, 2023. 89(2): p. 366-369.
Khanna, D., et al., A 24‐Week, Phase IIa, Randomized, Double‐Blind, Placebo‐Controlled Study of Ziritaxestat in Early Diffuse Cutaneous Systemic Sclerosis. Arthritis & Rheumatology, 2023. 75(8): p. 1434-1444.
Radić, M., et al., Beneficial effects of Helicobacter pylori eradication in systemic sclerosis patients. Wiener klinische Wochenschrift, 2023. 135(15): p. 414-419.
Tandaipan, J., et al., Immunoglobulins in systemic sclerosis management. A large multicenter experience. Autoimmunity Reviews, 2023: p. 103441.
Senet, P., et al., Efficacy and safety of botulinum toxin in adults with Raynaud’s phenomenon secondary to systemic sclerosis: a multicenter, randomized, double‐blind, placebo‐controlled study. Arthritis & Rheumatology, 2023. 75(3): p. 459-467.
Herrick, A.L., et al., A phase 2 trial investigating the effects of the angiotensin II type 2 receptor agonist C21 in systemic sclerosis-related Raynaud’s. Rheumatology, 2023. 62(2): p. 824-828.